Prevalence of Multidrug Resistant Tuberculosis by Xpert MTB/RIF Ultra and Xpert XDR Assay Among Newly Diagnosed Cases

Publication date: Nov 15, 2024

Tuberculosis (TB) is one of the major public health threats, competing with the human immunodeficiency virus (HIV) as the cause of death due to infectious diseases worldwide. Multi drug-resistant Mycobacterium tuberculosis (MDR-TB) is one of the leading causes of death in the world. The resource constraints make it difficult to diagnose and monitor the cases of MDR-TB. GeneXpert is a recognized tool used to diagnose the patients of pulmonary tuberculosis in clinical settings across the globe MDR Multidrug-resistant tuberculosis (MDR-TB), caused by Mycobacterium tuberculosis that is resistant to both isoniazid and rifampicin with or without resistance to other drugs According to current World Health Organization and the International Union Against Tuberculosis and Lung Disease estimates, the median prevalence of MDR-TB has been 1. 1% in newly diagnosed patients. The proportion, however, is considerably higher (median prevalence, 7%) in patients who have previously received anti-TB treatment. XDR tuberculosis is caused by a strain of Mycobacterium tuberculosis resistant to isoniazid and rifampin (which defines MDR tuberculosis) in addition to any fluoroquinolone and at least one of the three following injectable drugs: capreomycin, kanamycin, and amikacin The main causes of the spread of resistant TB are weak medical Systems, amplification of resistance patterns through incorrect treatment, and transmission in communities and facilities. Although patients harboring MDR and XDR strains present a formidable challenge for treatment, cure is often possible with early identification of resistance and use of a properly designed regimen.

Concepts Keywords
Fluoroquinolone Assay
Immunodeficiency Diagnosed
Mycobacterium Mdr
Newly Mtb
Tuberculosis Multidrug
Prevalence
Resistance
Resistant
Rif
Tb
Treatment
Tuberculosis
Ultra
Xdr
Xpert

Semantics

Type Source Name
disease MESH Tuberculosis
pathway KEGG Tuberculosis
disease IDO assay
disease IDO immunodeficiency
disease MESH cause of death
disease MESH infectious diseases
disease MESH pulmonary tuberculosis
disease MESH Multidrug-resistant tuberculosis
drug DRUGBANK Isoniazid
drug DRUGBANK Rifampicin
disease MESH Lung Disease
drug DRUGBANK Capreomycin
drug DRUGBANK Kanamycin
drug DRUGBANK Amikacin
disease MESH causes

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *